“According to a new report published by Introspective Market Research, titled, Mice Model Market by Type, Application, and End User, The Global Mice Model Market Size Was Valued at USD 1.42 Billion in 2024 and is Projected to Reach USD 2.59 Billion by 2035, Growing at a CAGR of 5.6% from 2025–2035.”
The Mice Model Market plays a critical role in preclinical research, enabling scientists to study disease mechanisms, drug efficacy, and safety before progressing to human clinical trials. Mouse models are extensively used due to their genetic similarity to humans, short reproductive cycles, and adaptability to genetic modification. These attributes make mice indispensable tools across biomedical research, pharmaceutical development, and academic studies.
Advancements in genetic engineering technologies, such as CRISPR/Cas9 and transgenic techniques, have significantly enhanced the precision and applicability of mice models. These innovations allow researchers to replicate complex human diseases, including cancer, neurological disorders, and autoimmune conditions, with greater accuracy. As a result, mice models continue to outperform traditional in-vitro methods in predicting clinical outcomes.
Growing investments in life sciences research, coupled with rising demand for personalized medicine, are further strengthening the market outlook. Pharmaceutical and biotechnology companies increasingly rely on mice models to accelerate drug discovery pipelines, reduce development risks, and comply with stringent regulatory requirements worldwide.
Market Segmentation
The Mice Model Market is segmented into Type, Application, and End User.
- By Type, the market is categorized into Inbred Mice, Outbred Mice, Genetically Engineered Mice, and Hybrid Mice.
- By Application, the market is categorized into Oncology, Immunology, Neurology, Cardiovascular Diseases, and Infectious Diseases.
- By End User, the market is categorized into Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, and Contract Research Organizations (CROs).
Growth Driver
One of the primary growth drivers of the mice model market is the rapid expansion of pharmaceutical and biotechnology R&D activities. Drug discovery processes increasingly depend on reliable and reproducible animal models to evaluate toxicity, pharmacokinetics, and therapeutic efficacy. Mice models provide high translational value, helping researchers identify promising drug candidates early in development. Additionally, the growing prevalence of chronic and genetic diseases worldwide has intensified the need for advanced preclinical testing platforms, further driving sustained demand for specialized mice models across research ecosystems.
Market Opportunity
A significant market opportunity lies in the rising adoption of genetically engineered and humanized mice models. These advanced models closely mimic human biological responses, enabling more accurate disease modeling and personalized medicine research. Emerging economies are also investing heavily in research infrastructure and life sciences innovation, opening new avenues for market expansion. Furthermore, collaborations between academic institutions, CROs, and biotech firms are creating opportunities for customized mice model development, enhancing market penetration and long-term growth prospects.
Detailed Segmentation
Mice Model Market, Segmentation
The Mice Model Market is segmented on the basis of Type, Application, and End User.
By Type:
The Type segment is further classified into Inbred Mice, Outbred Mice, and Genetically Engineered Mice. Among these, the Genetically Engineered Mice sub-segment accounted for the highest market share in 2024. This dominance is attributed to their extensive use in studying complex genetic disorders, cancer biology, and immune system responses. These models allow precise gene manipulation, enabling reproducible and clinically relevant research outcomes, making them highly preferred in advanced biomedical research.
By Application:
The Application segment is further classified into Oncology, Immunology, Neurology, and Cardiovascular Diseases. Among these, the Oncology sub-segment accounted for the highest market share in 2024. The rising global cancer burden and continuous development of targeted therapies have increased reliance on mice models for tumor biology studies, drug screening, and immunotherapy research, reinforcing this segment’s leadership position.
Some of The Leading/Active Market Players Are-
• Charles River Laboratories (USA)
• The Jackson Laboratory (USA)
• Taconic Biosciences (USA)
• Envigo (USA)
• Janvier Labs (France)
• GenOway (France)
• Crown Bioscience (USA)
• Trans Genic Inc. (Japan)
• Inotiv Inc. (USA)
• Hera BioLabs (USA)
• Shanghai Model Organisms Center (China)
• Cyagen Biosciences (China)
• Pharmaron (China)
• Vital River Laboratories (China)
• PolyGene AG (Switzerland)
and other active players.
Key Industry Developments
In March 2024, a leading preclinical research organization expanded its genetically engineered mice portfolio to support oncology and immunology research.
This expansion focused on accelerating drug discovery timelines by offering highly specialized disease-specific mice models tailored for pharmaceutical and biotech clients.
In September 2024, a global biotechnology company entered a strategic collaboration with an academic institute to develop next-generation humanized mice models.
The partnership aims to enhance translational research capabilities, particularly in immunotherapy and infectious disease studies, strengthening innovation across preclinical research.
Key Findings of the Study
• Genetically engineered mice dominate the market due to high research applicability
• Oncology remains the leading application segment globally
• North America holds the largest market share
• Rising R&D investments and chronic disease prevalence drive growth
• Technological advancements are shaping future market trends
